Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 92

Sort by

Sort Order Select

Journal Articles

Phase I Trial Combining Venetoclax with G-CSF, Cladribine, Cytarabine, and Mitoxantrone (CLAG-M) for Patients with High-Grade Myeloid Neoplasms

Suravi Raychaudhuri, Ted Gooley, Zach Gill, Allegra Rasmussen, Anna B. Halpern, Jacob S. Appelbaum, Cristina Maria Ghiuzeli, Paul C. Hendrie, Ryan D Cassaday, Roland B. Walter, Elihu Estey, Mary-Elizabeth M. Percival

Blood (2023) 142 (Supplement 1): 2897.

https://doi.org/10.1182/blood-2023-181582

Published: 2023

Journal Articles

Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal

Elihu Estey, Robert P. Hasserjian, Hartmut Döhner

Blood (2022) 139 (3): 323–332.

https://doi.org/10.1182/blood.2021011304

Published: 2022

Journal Articles

Long-term outcome of acute promyelocytic leukemia treated with all- trans -retinoic acid, arsenic trioxide, and gemtuzumab

Blood (2017) 129 (10): 1275–1283.

https://doi.org/10.1182/blood-2016-09-736686

Published: 2017

Journal Articles

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Blood (2017) 129 (4): 424–447.

https://doi.org/10.1182/blood-2016-08-733196

Published: 2017

Journal Articles

Long Term Outcome of Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid, Arsenic Trioxide with or without Gemtuzumab Ozogamicin

Blood (2015) 126 (23): 3776.

https://doi.org/10.1182/blood.V126.23.3776.3776

Published: 2015

Journal Articles

Current challenges in clinical development of “targeted therapies”: the case of acute myeloid leukemia

Elihu Estey, Ross L. Levine, Bob Löwenberg

Blood (2015) 125 (16): 2461–2466.

https://doi.org/10.1182/blood-2015-01-561373

Published: 2015

Journal Articles

The NCI common toxicity criteria and treatment-associated mortality in acute myeloid leukemia

Joshua R. Veatch, Vicky Sandhu, Pamela S. Becker, John M. Pagel, Frederick R. Appelbaum, Elihu Estey

Blood (2013) 122 (2): 293–294.

https://doi.org/10.1182/blood-2013-03-492835

Published: 2013

Journal Articles

Be quick, but don't hurry

Elihu Estey

Blood (2012) 119 (23): 5342–5343.

https://doi.org/10.1182/blood-2012-04-418574

Published: 2012

Journal Articles

Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation

Min Fang, Barry Storer, Elihu Estey, Megan Othus, Lisa Zhang, Brenda M. Sandmaier, Frederick R. Appelbaum

Blood (2011) 118 (6): 1490–1494.

https://doi.org/10.1182/blood-2011-02-339721

Published: 2011

Includes: Supplemental data

Journal Articles

The times they are a-changin'

Elihu Estey

Blood (2011) 117 (6): 1774–1775.

https://doi.org/10.1182/blood-2010-11-318444

Published: 2011

Journal Articles

Adhesion Receptor Expression by Acute Myeloid Leukemia (AML) Bone Marrow Derived or Circulating Blasts and AML Stem Cells: The Key to Overcoming Chemoresistance.

Pamela S. Becker, MD, PhD, Sylvia Chien, Mikhail Roshal, MD, PhD, Brent Wood, MD, PhD, Elihu Estey, MD, Thalia Papayannopoulou, MD, Xin Zhao, MD, Soumit Basu, MD, PhD, Mark McGrath, Kenneth Kopecky, PhD, Frederick R Appelbaum, MD

Blood (2009) 114 (22): 2658.

https://doi.org/10.1182/blood.V114.22.2658.2658

Published: 2009

Journal Articles

Significant Association Between Promoter Polymorphism of the Erythropoietin Gene and Myelodysplastic Syndrome.

Wanlong Ma, Hagop Kantarjian, MD, Ke Zhang, XI Zhang, Xiuqiang Wang, Zhong Zhang, MD, PhD, Chen-Hsiung Yeh, Anthony Sferruzza, PhD, Susan O'Brien, Elihu Estey, MD, Maher Albitar, M.D.

Blood (2009) 114 (22): 3825.

https://doi.org/10.1182/blood.V114.22.3825.3825

Published: 2009

Journal Articles

G-CSF Priming, Clofarabine and High Dose Cytarabine (GCLAC) for Relapsed or Refractory Acute Myeloid Leukemia (AML).

Pamela S. Becker, MD, PhD, Elihu Estey, MD, Stephen Petersdorf, MD, Barry E Storer, PhD, Frederick R Appelbaum, MD

Blood (2009) 114 (22): 2068.

https://doi.org/10.1182/blood.V114.22.2068.2068

Published: 2009

Journal Articles

Clinical Significance of Circulating Ki-67 Protein and Caspase-3 Activity Levels in Patients with Acute Myeloid Leukemia.

Jean-Marie Bruey, Hagop M. Kantarjian, MD, Zeev Estrov, MD, Wanlong Ma, Chen-Hsiung Yeh, Anthony Sferruzza, PhD, Elihu Estey, MD, Maher Albitar, M.D.

Blood (2009) 114 (22): 3104.

https://doi.org/10.1182/blood.V114.22.3104.3104

Published: 2009

Journal Articles

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients

Mikkael A. Sekeres, Paul Elson, Matt E. Kalaycio, Anjali S. Advani, Edward A. Copelan, Stefan Faderl, Hagop M. Kantarjian, Elihu Estey

Blood (2009) 113 (1): 28–36.

https://doi.org/10.1182/blood-2008-05-157065

Published: 2009

Journal Articles

Impact of Pre-Transplant Minimal Residual Disease Assessed by Flow Cytometry on Outcome Following Myeloablative Hematopoietic Cell Transplantation for Patients with AML-CR1.

John M. Pagel, MD, PhD, Ted Gooley, Elihu Estey, Brent Wood, Frederick R. Appelbaum

Blood (2008) 112 (11): 3253.

https://doi.org/10.1182/blood.V112.11.3253.3253

Published: 2008

Journal Articles

Randomized Phase II Study of Combined Epigenetic Therapy: Decitabine Vs. Decitabine and Valproic Acid in MDS and AML

Jean-Pierre Issa, Ryan Castoro, Farhad Ravandi-Kashani, Stefan Faderl, Xuelin Huang, Elihu Estey, Gautam Borthakur, Gail Morris, Guillermo Garcia-Manero, Hagop M Kantarjian

Blood (2008) 112 (11): 228.

https://doi.org/10.1182/blood.V112.11.228.228

Published: 2008

Journal Articles

Phase I Trial of Clofarabine and High Dose Cytarabine with G-CSF Priming (G-CLAC) for Relapsed or Refractory Acute Myeloid Leukemia

Pamela S. Becker, MD, PhD, Elihu Estey, MD, Stephen Petersdorf, MD, Paul C. Hendrie, MD, PhD, John M. Pagel, MD, PhD, Derek Stirewalt, MD, Andrei Shustov, MD, Barry E. Storer, PhD, Frederick R. Appelbaum, MD

Blood (2008) 112 (11): 2964.

https://doi.org/10.1182/blood.V112.11.2964.2964

Published: 2008

Journal Articles

Pharmacodynamic Study of Phase 1/2 Trial of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Chemotherapy in Patients with Relapsed/Refractory AML.

Bing Z. Carter, PhD, Duncan H. Mak, Stephen Morris, Gautam Borthakur, MD, Elihu Estey, MD, Anna L. Byrd, RN, Marina Konopleva, MD, PhD, Hagop M. Kantarjian, MD, Michael Andreeff, MD, PhD

Blood (2008) 112 (11): 1943.

https://doi.org/10.1182/blood.V112.11.1943.1943

Published: 2008

Journal Articles

Liposomal Amphotericin B IV (LIPO AB) Once Per Week Is Effective in the Prevention of Invasive Fungal Infections (IFI) in Patients (Pts) with Acute Leukemia: Preliminary Analysis of a Randomized Trial.

Gloria Mattiuzzi, MD, Jorge Cortes, MD, Deborah Blamble, PHDP, Elihu Estey, MD, Hagop Kantarjian, MD

Blood (2007) 110 (11): 1824.

https://doi.org/10.1182/blood.V110.11.1824.1824

Published: 2007

NARROW

Phase I Trial Combining Venetoclax with G-CSF, Cladribine, Cytarabine, and Mitoxantrone (CLAG-M) for Patients with High-Grade Myeloid Neoplasms

Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal

Long-term outcome of acute promyelocytic leukemia treated with all- trans -retinoic acid, arsenic trioxide, and gemtuzumab

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Long Term Outcome of Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid, Arsenic Trioxide with or without Gemtuzumab Ozogamicin

Current challenges in clinical development of “targeted therapies”: the case of acute myeloid leukemia

The NCI common toxicity criteria and treatment-associated mortality in acute myeloid leukemia

Be quick, but don't hurry

Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation

The times they are a-changin'

Adhesion Receptor Expression by Acute Myeloid Leukemia (AML) Bone Marrow Derived or Circulating Blasts and AML Stem Cells: The Key to Overcoming Chemoresistance.

Significant Association Between Promoter Polymorphism of the Erythropoietin Gene and Myelodysplastic Syndrome.

G-CSF Priming, Clofarabine and High Dose Cytarabine (GCLAC) for Relapsed or Refractory Acute Myeloid Leukemia (AML).

Clinical Significance of Circulating Ki-67 Protein and Caspase-3 Activity Levels in Patients with Acute Myeloid Leukemia.

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients

Impact of Pre-Transplant Minimal Residual Disease Assessed by Flow Cytometry on Outcome Following Myeloablative Hematopoietic Cell Transplantation for Patients with AML-CR1.

Randomized Phase II Study of Combined Epigenetic Therapy: Decitabine Vs. Decitabine and Valproic Acid in MDS and AML

Phase I Trial of Clofarabine and High Dose Cytarabine with G-CSF Priming (G-CLAC) for Relapsed or Refractory Acute Myeloid Leukemia

Pharmacodynamic Study of Phase 1/2 Trial of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Chemotherapy in Patients with Relapsed/Refractory AML.

Liposomal Amphotericin B IV (LIPO AB) Once Per Week Is Effective in the Prevention of Invasive Fungal Infections (IFI) in Patients (Pts) with Acute Leukemia: Preliminary Analysis of a Randomized Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only